[A case of tongue cancer effectively treated with tegafur].
We administered a slow-release formulation of tegafur (SF-SP) to a patient with cancer of the tongue. We would like to report the findings of this case which showed clear improvement. SF-SP was administered at 800 mg/day to a 58 year-old male for cancer of the tongue (T4N1). By the 17th day after the start of SF-SP administration, the tumor had shrunk, and by the 37th day the submandibular lymph nodes could not be located by touch. At the completion of the test on the 60th day, no cancer cells were detected. Following the completion of the test, there have been no symptoms of recurrence and a complete response was observed. At present, we are continuing administration of SF-SP and making observations.
Yokokura
Y
Y
Dept. of Oral Surgery, Dokkyo University School of Medicine.
Sakamoto
H
H
Sasaki
T
T
Imai
Y
Y
Shinohara
M
M
Asakura
S
S
Shimada
I
I
Fukuda
M
M
Nagashima
T
T
Fujibayashi
T
T
D000230:Adenocarcinoma / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D014062:Tongue Neoplasms / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D005641:Tegafur